Secondly, Kangmei Pharmaceutical is facing enormous competitive pressure in the industry. With the gradual opening of the domestic pharmaceutical market and the intensification of competition, the market share of Kangmei Pharmaceutical has been declining. At the same time, the company's investment in innovative drug research and development is insufficient, resulting in slow product update and lack of sufficient competitiveness. For Kangmei Pharmaceutical, in order to survive and develop in the fierce market competition, it is necessary to improve product quality and innovation ability.
Finally, there are problems in the management of Kangmei Pharmaceutical. The company's internal management is chaotic, the company's senior management changes frequently, and there is a lack of stable leadership and management team. At the same time, the company also has shortcomings in marketing and brand building, and has not formed obvious brand advantages and core competitiveness. To some extent, these problems have caused Kangmei Pharmaceutical to be unable to obtain reasonable market recognition and investors' optimism, and its share price is naturally difficult to rise.